RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CRISPR Therapeutics Stock

CRISPR Therapeutics Revenue 2024

CRISPR Therapeutics Revenue

16.28 M USD

Ticker

CRSP

ISIN

CH0334081137

WKN

A2AT0Z

In 2024, CRISPR Therapeutics's sales reached 16.28 M USD, a -95.61% difference from the 371.21 M USD sales recorded in the previous year.

The CRISPR Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2030e8.65-
2029e3.6-
2028e2.15-
2027e1.46-
2026e0.67-
2025e0.14-
2024e0.02-
20230.37-
20220-
20210.92-
20200-
20190.29-
20180-
20170.04-
20160.01-
20150-
2014--

CRISPR Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CRISPR Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CRISPR Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CRISPR Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CRISPR Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CRISPR Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CRISPR Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CRISPR Therapeutics’s growth potential.

CRISPR Therapeutics Revenue, EBIT and net profit per share

DateCRISPR Therapeutics RevenueCRISPR Therapeutics EBITCRISPR Therapeutics Net Income
2030e8.65 B undefined3.77 B undefined3.38 B undefined
2029e3.6 B undefined2.12 B undefined1.03 B undefined
2028e2.15 B undefined420.38 M undefined415.64 M undefined
2027e1.46 B undefined60.91 M undefined82.8 M undefined
2026e670.12 M undefined-206.59 M undefined-262.84 M undefined
2025e139.72 M undefined-469.99 M undefined-439.66 M undefined
2024e16.28 M undefined-568.39 M undefined-452.67 M undefined
2023371.21 M undefined-222.54 M undefined-153.61 M undefined
20221.2 M undefined-673.2 M undefined-650.2 M undefined
2021915 M undefined373.5 M undefined377.7 M undefined
2020700,000 undefined-354.4 M undefined-348.9 M undefined
2019289.6 M undefined46.7 M undefined66.9 M undefined
20183.1 M undefined-158.9 M undefined-165 M undefined
201741 M undefined-64.6 M undefined-68.4 M undefined
20165.2 M undefined-68.1 M undefined-23.2 M undefined
2015200,000 undefined-25.7 M undefined-25.5 M undefined
20140 undefined-6.6 M undefined-7 M undefined

CRISPR Therapeutics stock margins

The CRISPR Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CRISPR Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CRISPR Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CRISPR Therapeutics's sales revenue. A higher gross margin percentage indicates that the CRISPR Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CRISPR Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CRISPR Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CRISPR Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CRISPR Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CRISPR Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CRISPR Therapeutics Margin History

CRISPR Therapeutics Gross marginCRISPR Therapeutics Profit marginCRISPR Therapeutics EBIT marginCRISPR Therapeutics Profit margin
2030e0 %43.58 %39.05 %
2029e0 %58.91 %28.56 %
2028e0 %19.55 %19.33 %
2027e0 %4.17 %5.67 %
2026e0 %-30.83 %-39.22 %
2025e0 %-336.38 %-314.67 %
2024e0 %-3,491.14 %-2,780.39 %
20230 %-59.95 %-41.38 %
20220 %-56,100 %-54,183.33 %
20210 %40.82 %41.28 %
20200 %-50,628.57 %-49,842.86 %
20190 %16.13 %23.1 %
20180 %-5,125.81 %-5,322.58 %
20170 %-157.56 %-166.83 %
20160 %-1,309.62 %-446.15 %
20150 %-12,850 %-12,750 %
20140 %0 %0 %

CRISPR Therapeutics Aktienanalyse

What does CRISPR Therapeutics do?

CRISPR Therapeutics AG is a company specializing in the development of therapies based on the gene editing technology CRISPR-Cas9. The company was founded in 2013 in Basel, Switzerland and is now headquartered in Zug, Switzerland. CRISPR Therapeutics is listed on the NASDAQ stock exchange and also has offices in the USA and London. CRISPR Therapeutics AG's history is closely linked to the discovery and development of the CRISPR-Cas9 technology. This revolutionary technique allows for the targeted modification, repair or elimination of certain genes in the genome of organisms. The technology was first discovered in the 1990s, but it was only in recent years with the development of CRISPR-Cas9 that it became possible to apply this technique in medical research. The goal of CRISPR Therapeutics AG is to use the CRISPR-Cas9 technology to develop therapies for life-threatening genetic diseases. The company works closely with the academic community and industry to develop innovative therapies and bring them through clinical trials. The business model of CRISPR Therapeutics AG is based on the development and commercialization of therapies based on the CRISPR-Cas9 technology. This involves using the technology to treat the genetic causes of serious diseases such as cystic fibrosis, sickle cell anemia, beta-thalassemia, or certain types of cancer. The company has a number of products in its pipeline and works closely with partners such as Vertex Pharmaceuticals and Bayer. CRISPR Therapeutics operates in the biotechnology industry and is divided into various divisions. For example, there is the research and development (R&D) division, which focuses on developing new therapies based on the CRISPR-Cas9 technology. Here, the company works on its own research projects as well as joint research projects with partners. There is also a clinical studies department that aims to test new therapies, prove their efficacy and safety in humans, and produce approved therapeutics. An example of a current product from the company is the CTX001 therapy, which involves stem cell transplantation using genetically modified stem cells from healthy donors to produce genetically error-free blood cells in the patient's body. CTX001 is currently in phase 1/2a clinical trials for the treatment of beta-thalassemia and sickle cell anemia, and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. In summary, CRISPR Therapeutics AG is a company in the biotechnology industry specializing in the development and commercialization of therapies based on the CRISPR-Cas9 technology. The company has a number of products in its pipeline and works closely with partners to develop innovative therapies and bring them through clinical trials. With the CRISPR-Cas9 technology, there is the potential to combat genetic diseases, which could have a significant impact on the treatment of diseases in the future. CRISPR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding CRISPR Therapeutics's Sales Figures

The sales figures of CRISPR Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing CRISPR Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize CRISPR Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in CRISPR Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about CRISPR Therapeutics stock

How much revenue did CRISPR Therapeutics generate this year?

CRISPR Therapeutics has achieved a revenue of 16.28 M USD this year.

How much was the turnover of the company CRISPR Therapeutics compared to the previous year?

The revenue of CRISPR Therapeutics has increased by -95.61% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of CRISPR Therapeutics?

The revenue of CRISPR Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of CRISPR Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of CRISPR Therapeutics so important for investors?

The revenue of CRISPR Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does CRISPR Therapeutics pay?

Over the past 12 months, CRISPR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CRISPR Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CRISPR Therapeutics?

The current dividend yield of CRISPR Therapeutics is .

When does CRISPR Therapeutics pay dividends?

CRISPR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CRISPR Therapeutics?

CRISPR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CRISPR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CRISPR Therapeutics located?

CRISPR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CRISPR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CRISPR Therapeutics from 11/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/26/2024.

When did CRISPR Therapeutics pay the last dividend?

The last dividend was paid out on 11/26/2024.

What was the dividend of CRISPR Therapeutics in the year 2023?

In the year 2023, CRISPR Therapeutics distributed 0 USD as dividends.

In which currency does CRISPR Therapeutics pay out the dividend?

The dividends of CRISPR Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CRISPR Therapeutics

Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.